文献速递前列腺增生与排尿功能障碍

米拉贝隆治疗≥65岁伴急迫性尿失禁的膀胱过度活动症:IV期随机对照PILLAR研究

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
PubMed 文献 · Eur Urol · 2019-11-13

PILLAR研究为IV期双盲随机安慰剂对照试验,纳入≥65岁社区居住的膀胱过度活动症伴急迫性尿失禁患者,先经2周安慰剂导入,随后按1:1随机接受米拉贝隆25mg/d或安慰剂12周,第4或8周可酌情增至50mg/d。结果显示米拉贝隆在减少每日排尿次数和尿失禁次数等主要终点上显著优于安慰剂,安全性与已知特征一致。

要点

  • 米拉贝隆显著改善≥65岁OAB患者的每日排尿次数和尿失禁次数。
  • 次要终点如每次排尿量、急迫感和急迫性尿失禁次数也显著改善。
  • 安全性和耐受性与米拉贝隆已知特征一致。

核心结论

  • 在≥65岁伴急迫性尿失禁的OAB患者中,米拉贝隆治疗12周的有效性、安全性和耐受性得到确认。

研究设计与样本

  • IV期双盲随机安慰剂对照研究,纳入社区居住、≥65岁、OAB病程≥3个月的患者。
  • 经2周安慰剂导入后,符合条件者按1:1随机接受米拉贝隆25mg/d或匹配安慰剂治疗12周,第4或8周可酌情增至50mg/d。

主要发现

  • 从基线至治疗结束,米拉贝隆组在每日平均排尿次数、每日平均尿失禁次数、每次排尿平均尿量、每日平均急迫感次数和每日平均急迫性尿失禁次数方面均较安慰剂组有统计学显著改善。

关键数值与推荐

  • 共同主要终点:从基线至治疗结束的每日平均排尿次数和每日平均尿失禁次数的变化。
  • 次要终点:从基线至治疗结束的每次排尿平均尿量、每日平均急迫感次数和每日平均急迫性尿失禁次数的变化。

临床怎么用

  • 对于≥65岁伴急迫性尿失禁的OAB患者,可考虑使用米拉贝隆25mg/d起始,酌情增至50mg/d,治疗12周可改善症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The majority of patients with overactive bladder (OAB) are aged >65yr. There has been no prospectively designed study assessing treatment efficacy with the β3-adrenoreceptor agonist, mirabegron, specifically in this age group. OBJECTIVE: A phase IV study comparing flexibly dosed mirabegron versus placebo in elderly patients with OAB and urgency incontinence. DESIGN, SETTING, AND PARTICIPANTS: Community-dwelling patients aged ≥65yr with OAB for ≥3mo. INTERVENTION: Following a 2-wk placebo run in, patients with one or more incontinence episodes, three or more urgency episodes, and an average of eight or more micturitions/24h were randomised 1:1 to double-blind 25mg/d mirabegron or matched placebo, for 12wk. After week 4 or 8, the dose could be increased to 50mg/d mirabegron/matched placebo based on patient and investigator discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Coprimary endpoints: change from baseline to end of treatment (EOT) in the mean numbers of micturitions/24h and incontinence episodes/24h. Secondary endpoints: change from baseline to EOT in the mean volume voided/micturition, mean number of urgency episodes/24h, and mean number of urgency incontinence episodes/24h. Analysis of covariance (ANCOVA) was used for the mean number of micturitions/24h, mean volume voided/micturition, and mean number of urgency episodes/24h. Stratified rank ANCOVA was used for the mean numbers of incontinence episodes/24h and urgency incontinence episodes/24h. RESULTS AND LIMITATIONS: Statistically significant improvements were observed for mirabegron versus placebo in change from baseline to EOT in the mean number of micturitions/24h, mean number of incontinence episodes/24h, mean volume voided/micturition, mean number of urgency episodes/24h, and mean number of urgency incontinence episodes/24h. Safety and tolerability were consistent with the known mirabegron safety profile. CONCLUSIONS: Mirabegron efficacy, safety, and tolerability over 12 wk were confirmed in patients aged ≥65yr with OAB and incontinence. PATIENT SUMMARY: We examined the effect of mirabegron compared with placebo in people aged 65yr or older with overactive bladder and incontinence. Mirabegron improved the symptoms of overactive bladder compared with placebo. Side effects were similar to those already known for mirabegron.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2019. PMID: 31733990. doi:10.1016/j.eururo.2019.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。